Get the Stockscreener App
14.40
0.35%
0.05
After Hours:
14.40
Avalo Therapeutics Inc stock is traded at $14.40, with a volume of 378.08K.
It is up +0.35% in the last 24 hours and down -13.62% over the past month.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$14.35
Open:
$14.31
24h Volume:
378.08K
Relative Volume:
1.09
Market Cap:
$266.58M
Revenue:
$1.93M
Net Income/Loss:
$-7.96M
P/E Ratio:
-0.00408
EPS:
-3530.8178
Net Cash Flow:
$-36.78M
1W Performance:
+9.51%
1M Performance:
-13.62%
6M Performance:
+53.85%
1Y Performance:
+87.50%
1-Day Range:
$13.93
$14.53
1-Week Range:
$13.19
$14.81
52-Week Range:
$3.39
$20.72
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
14.40 | 265.66M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa - Yahoo Finance
AVTX: Phase 2b LOTUS trial for AVTX-009 in HS nears Q2 data, targeting rapid phase 3 and new indications - TradingView
Dow Update: Will Avalo Therapeutics Inc outperform the market in YEARRate Hike & Long-Term Capital Growth Ideas - baoquankhu1.vn
Avalo Therapeutics shares jump as Guggenheim starts coverage with buy - MSN
Avalo Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Biotech firm Avalo will stream two investor talks in February - Stock Titan
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case - Benzinga
Guggenheim Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - Nasdaq
Guggenheim Initiates Coverage on Avalo Therapeutics (AVTX) with - GuruFocus
Avalo Therapeutics stock rises after Guggenheim initiates with Buy rating By Investing.com - Investing.com Australia
Avalo Therapeutics stock rises after Guggenheim initiates with Buy rating - Investing.com
Guggenheim Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX) - MarketBeat
Guggenheim initiates Avalo Therapeutics stock with Buy rating on IL-1β therapy - Investing.com UK
Guggenheim initiates Avalo Therapeutics stock with Buy rating on IL-1β therapy By Investing.com - Investing.com India
Avalo Therapeutics Completes Enrollment for AVTX-009 Trial - Intellectia AI
Avalo Therapeutics Highlights AVTX-009 Progress in HS - TipRanks
Aug Update: Is Avalo Therapeutics Inc in a bullish channelJuly 2025 Short Interest & Expert Curated Trade Setups - baoquankhu1.vn
Avalo Therapeutics Advances in Hidradenitis Suppurativa Treatment with AVTX-009 Study - MSN
Patterns Watch: Is Avalo Therapeutics Inc a potential multi bagger2025 Top Gainers & Safe Entry Zone Tips - baoquankhu1.vn
Market Pulse: What is the long term forecast for Renovaro Inc stock2025 Geopolitical Influence & Comprehensive Market Scan Reports - baoquankhu1.vn
Gainers Report: Can Avalo Therapeutics Inc outperform under higher oil pricesJuly 2025 Price Swings & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $32.71 Consensus Price Target from Analysts - Defense World
Market Wrap: What is the target price for DXLG stock2025 Retail Activity & AI Based Trade Execution Alerts - baoquankhu1.vn
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 38.2% in December - MarketBeat
Avalo Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of trial data By Investing.com - Investing.com South Africa
Avalo Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of trial data - Investing.com Nigeria
Avalo Therapeutics' (AVTX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Aug Summary: What analysts say about Avalo Therapeutics Inc stockTreasury Yields & Detailed Earnings Play Alerts - baoquankhu1.vn
Avalo Therapeutics (AVTX) Gets 'Buy' Rating Reiteration from HC Wainwright | AVTX Stock News - GuruFocus
Retail Trends: Is Avalo Therapeutics Inc stock a safe investment in uncertain markets2025 Winners & Losers & Reliable Momentum Entry Alerts - Bộ Nội Vụ
Insider Sell: Is Avalo Therapeutics Inc stock positioned for digital transformationJuly 2025 Technicals & AI Optimized Trading Strategy Guides - Bộ Nội Vụ
Will Avalo Therapeutics Inc. stock benefit from AI adoptionJuly 2025 Retail & Step-by-Step Trade Execution Guides - Улправда
Will Avalo Therapeutics Inc. stock split attract more investorsEarnings Overview Summary & Risk Controlled Swing Alerts - Улправда
Moving Averages: Will Avalo Therapeutics Inc. stock split attract more investorsWall Street Watch & Safe Entry Trade Signal Reports - Улправда
Is Avalo Therapeutics Inc. stock positioned well for digital economy2025 Risk Factors & High Accuracy Swing Trade Signals - Улправда
Avalo Therapeutics Reports Q3 2025 Financial Results - MSN
Avalo Therapeutics Files $750 Million Mixed Shelf - marketscreener.com
Avalo Therapeutics files for mixed shelf of up to $750 millionSEC filing - marketscreener.com
What margin trends mean for Avalo Therapeutics Inc. stockSwing Trade & Technical Pattern Based Signals - Улправда
Aug Momentum: Will Avalo Therapeutics Inc. stock benefit from AI adoptionAnalyst Downgrade & Accurate Intraday Trading Signals - ulpravda.ru
Is Avalo Therapeutics Inc. stock attractive after correctionPortfolio Risk Summary & Stepwise Entry and Exit Trade Signals - Улправда
Why analysts remain bullish on Avalo Therapeutics Inc. stockSwing Trade & Fast Gaining Stock Strategy Reports - ulpravda.ru
Options Flow: What margin trends mean for Avalo Therapeutics Inc stockGap Down & Weekly Sector Rotation Insights - Bộ Nội Vụ
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV), Avalo Therapeutics (AVTX) and Lifestance Health Group (LFST) - The Globe and Mail
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Would You Still Hold Avalo Therapeutics Stock If It Fell 30%? - Trefis
How rising interest rates impact Avalo Therapeutics Inc. stock2025 Trading Recap & Capital Protection Trade Alerts - DonanımHaber
Avalo Therapeutics (NASDAQ:AVTX) Upgraded by Mizuho to "Strong-Buy" Rating - MarketBeat
Will Avalo Therapeutics Inc. (C6K0) stock announce special dividend2025 Market Outlook & Fast Moving Stock Trade Plans - DonanımHaber
Can Avalo Therapeutics Inc. (C6K0) stock survive global slowdownWeekly Stock Summary & Fast Entry Momentum Alerts - DonanımHaber
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):